Learn about the adverse reactions of cabotegravir/rilpivirine injection suspension

Cabotegravir/rilpivirine injection suspension (cabotegravir and rilpivirine), as an innovative long-acting injection solution, provides a new treatment option for adults and adolescents aged 12 years and above infected with HIV-1 virus. The drug consists of two active ingredients: cabotegravir and rilpivirine, which act as HIV-1 integrase strand transfer inhibitors and non-nucleoside reverse transcriptase inhibitors respectively. They jointly act on the key links of viral replication and effectively inhibit viral activity.

In clinical application, cabotegravir/rilpivirine injection suspension has demonstrated good antiviral effects and brought hope to patients. However, like many medications, it can be associated with a range of adverse reactions. Common side effects are mostly concentrated at the injection site, such as pain, tenderness, lumps, swelling, redness, itching and even bruising. Some patients may also experience symptoms such as fever, fatigue, headache, muscle or bone pain, nausea, sleep problems, dizziness, and rash.

In addition to these relatively mild reactions, cabotegravir/rilpivirine injection suspension may also cause some serious adverse reactions. Symptoms such as allergies, difficulty breathing, stomach cramps, sweating, numbness in the mouth, back or chest pain, anxiety, elevated blood pressure, jaundice, dark or tea-colored urine, nausea and vomiting, loss of appetite, and pain on the right side of the stomach may be symptoms of adverse drug reactions. Additionally, depression or mood changes are side effects of concern.
In the face of these adverse reactions, patients should communicate with their doctors promptly and describe their symptoms in detail. For minor adverse reactions, doctors may recommend adjusting the medication or taking symptomatic treatment measures. Once serious adverse reactions occur, patients should seek medical treatment immediately so that doctors can quickly assess the condition and take appropriate treatment measures. Close monitoring of the patient and close cooperation with the physician are essential during use of cabotegravir/rilpivirine injection suspension.
Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212888s011lbl.pdf